What is Generate Biomedicines, Inc. 's change in AR?

Generate Biomedicines, Inc. (GENB) reported change in AR of $0 in Q1 2026.

What does change in AR mean?

Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.

Generate Biomedicines, Inc. GENB Change in AR

Change in AR at other companies

MYR GroupMYRG

$32.57M+139%

RepligenRGEN

-$3.19M-132%

AppFolioAPPF

$7.44M+139%

CHE

ChemedCHE

$32.9M-51.2%

Boyd GamingBYD

-$5.58M+75.0%

MGY

Magnolia Oil & Gas CorporationMGY

$42.35M+276%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's change in AR?: Generate Biomedicines, Inc. (GENB) reported change in AR of $0 in Q1 2026.
What does change in AR mean?: Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.